ERBB2 and neoplasm: First, RT or TRT agents can bind to specific cancer‐expressing markers (such as HER2) with acceptable affinity and can deliver β‐ or α‐particles for localised irradiation, which has demonstrated a potent ability for tumour targeting and tumour regression [18, 38, 56, 57].